Global Primary Biliary Cholangitis Therapeutics Market Research Report 2023
Global Primary Biliary Cholangitis Therapeutics Market Overview:
Global Primary Biliary Cholangitis Therapeutics Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Primary Biliary Cholangitis Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Primary Biliary Cholangitis Therapeutics Market
The Primary Biliary Cholangitis Therapeutics Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Primary Biliary Cholangitis Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Primary Biliary Cholangitis Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Primary Biliary Cholangitis Therapeutics Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Primary Biliary Cholangitis Therapeutics market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Primary Biliary Cholangitis Therapeutics Market Segmentation
Global Primary Biliary Cholangitis Therapeutics Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Primary Biliary Cholangitis Therapeutics market has been segmented into:
OCALIVA
Ursodiol
Others
By Application, Primary Biliary Cholangitis Therapeutics market has been segmented into:
Hospital
Private Clinic
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Primary Biliary Cholangitis Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Primary Biliary Cholangitis Therapeutics market.
Top Key Players Covered in Primary Biliary Cholangitis Therapeutics market are:
Allergan Plc
Abbott Laboratories
Takeda Pharmaceutical Co. Ltd.
Eli Lilly and Co.
Intercept Pharmaceuticals Inc.
Objective to buy this Report:
1. Primary Biliary Cholangitis Therapeutics analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Primary Biliary Cholangitis Therapeutics market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Global Primary Biliary Cholangitis Therapeutics Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Primary Biliary Cholangitis Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Primary Biliary Cholangitis Therapeutics Market
The Primary Biliary Cholangitis Therapeutics Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Primary Biliary Cholangitis Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Primary Biliary Cholangitis Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Primary Biliary Cholangitis Therapeutics Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Primary Biliary Cholangitis Therapeutics market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Primary Biliary Cholangitis Therapeutics Market Segmentation
Global Primary Biliary Cholangitis Therapeutics Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Primary Biliary Cholangitis Therapeutics market has been segmented into:
OCALIVA
Ursodiol
Others
By Application, Primary Biliary Cholangitis Therapeutics market has been segmented into:
Hospital
Private Clinic
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Primary Biliary Cholangitis Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Primary Biliary Cholangitis Therapeutics market.
Top Key Players Covered in Primary Biliary Cholangitis Therapeutics market are:
Allergan Plc
Abbott Laboratories
Takeda Pharmaceutical Co. Ltd.
Eli Lilly and Co.
Intercept Pharmaceuticals Inc.
Objective to buy this Report:
1. Primary Biliary Cholangitis Therapeutics analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Primary Biliary Cholangitis Therapeutics market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
CHAPTER 1: INTRODUCTION
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 By Type
3.2 By Application
CHAPTER 4: MARKET LANDSCAPE
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
CHAPTER 5: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY TYPE
5.1 Primary Biliary Cholangitis Therapeutics Market Overview Snapshot and Growth Engine
5.2 Primary Biliary Cholangitis Therapeutics Market Overview
5.3 OCALIVA
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 OCALIVA: Geographic Segmentation
5.4 Ursodiol
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Ursodiol: Geographic Segmentation
5.5 Others
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2028F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Others: Geographic Segmentation
CHAPTER 6: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY APPLICATION
6.1 Primary Biliary Cholangitis Therapeutics Market Overview Snapshot and Growth Engine
6.2 Primary Biliary Cholangitis Therapeutics Market Overview
6.3 Hospital
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital: Geographic Segmentation
6.4 Private Clinic
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Private Clinic: Geographic Segmentation
6.5 Other
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Other: Geographic Segmentation
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Primary Biliary Cholangitis Therapeutics Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Primary Biliary Cholangitis Therapeutics Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Primary Biliary Cholangitis Therapeutics Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ALLERGAN PLC
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 ABBOTT LABORATORIES
7.4 TAKEDA PHARMACEUTICAL CO. LTD.
7.5 ELI LILLY AND CO.
7.6 INTERCEPT PHARMACEUTICALS INC.
CHAPTER 8: GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 OCALIVA
8.2.2 Ursodiol
8.2.3 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital
8.3.2 Private Clinic
8.3.3 Other
CHAPTER 9: NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 OCALIVA
9.4.2 Ursodiol
9.4.3 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital
9.5.2 Private Clinic
9.5.3 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 U.S.
9.6.2 Canada
9.6.3 Mexico
CHAPTER 10: EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 OCALIVA
10.4.2 Ursodiol
10.4.3 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital
10.5.2 Private Clinic
10.5.3 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Germany
10.6.2 U.K.
10.6.3 France
10.6.4 Italy
10.6.5 Russia
10.6.6 Spain
10.6.7 Rest of Europe
CHAPTER 11: ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 OCALIVA
11.4.2 Ursodiol
11.4.3 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital
11.5.2 Private Clinic
11.5.3 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 China
11.6.2 India
11.6.3 Japan
11.6.4 Singapore
11.6.5 Australia
11.6.6 New Zealand
11.6.7 Rest of APAC
CHAPTER 12: MIDDLE EAST & AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 OCALIVA
12.4.2 Ursodiol
12.4.3 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital
12.5.2 Private Clinic
12.5.3 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 Turkey
12.6.2 Saudi Arabia
12.6.3 Iran
12.6.4 UAE
12.6.5 Africa
12.6.6 Rest of MEA
CHAPTER 13: SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 OCALIVA
13.4.2 Ursodiol
13.4.3 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital
13.5.2 Private Clinic
13.5.3 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Brazil
13.6.2 Argentina
13.6.3 Rest of SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 By Type
3.2 By Application
CHAPTER 4: MARKET LANDSCAPE
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
CHAPTER 5: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY TYPE
5.1 Primary Biliary Cholangitis Therapeutics Market Overview Snapshot and Growth Engine
5.2 Primary Biliary Cholangitis Therapeutics Market Overview
5.3 OCALIVA
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 OCALIVA: Geographic Segmentation
5.4 Ursodiol
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Ursodiol: Geographic Segmentation
5.5 Others
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2028F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Others: Geographic Segmentation
CHAPTER 6: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY APPLICATION
6.1 Primary Biliary Cholangitis Therapeutics Market Overview Snapshot and Growth Engine
6.2 Primary Biliary Cholangitis Therapeutics Market Overview
6.3 Hospital
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital: Geographic Segmentation
6.4 Private Clinic
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Private Clinic: Geographic Segmentation
6.5 Other
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Other: Geographic Segmentation
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Primary Biliary Cholangitis Therapeutics Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Primary Biliary Cholangitis Therapeutics Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Primary Biliary Cholangitis Therapeutics Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ALLERGAN PLC
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 ABBOTT LABORATORIES
7.4 TAKEDA PHARMACEUTICAL CO. LTD.
7.5 ELI LILLY AND CO.
7.6 INTERCEPT PHARMACEUTICALS INC.
CHAPTER 8: GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 OCALIVA
8.2.2 Ursodiol
8.2.3 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital
8.3.2 Private Clinic
8.3.3 Other
CHAPTER 9: NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 OCALIVA
9.4.2 Ursodiol
9.4.3 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital
9.5.2 Private Clinic
9.5.3 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 U.S.
9.6.2 Canada
9.6.3 Mexico
CHAPTER 10: EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 OCALIVA
10.4.2 Ursodiol
10.4.3 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital
10.5.2 Private Clinic
10.5.3 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Germany
10.6.2 U.K.
10.6.3 France
10.6.4 Italy
10.6.5 Russia
10.6.6 Spain
10.6.7 Rest of Europe
CHAPTER 11: ASIA-PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 OCALIVA
11.4.2 Ursodiol
11.4.3 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital
11.5.2 Private Clinic
11.5.3 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 China
11.6.2 India
11.6.3 Japan
11.6.4 Singapore
11.6.5 Australia
11.6.6 New Zealand
11.6.7 Rest of APAC
CHAPTER 12: MIDDLE EAST & AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 OCALIVA
12.4.2 Ursodiol
12.4.3 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital
12.5.2 Private Clinic
12.5.3 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 Turkey
12.6.2 Saudi Arabia
12.6.3 Iran
12.6.4 UAE
12.6.5 Africa
12.6.6 Rest of MEA
CHAPTER 13: SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 OCALIVA
13.4.2 Ursodiol
13.4.3 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital
13.5.2 Private Clinic
13.5.3 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Brazil
13.6.2 Argentina
13.6.3 Rest of SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET COMPETITIVE RIVALRY
TABLE 005. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET THREAT OF NEW ENTRANTS
TABLE 006. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET THREAT OF SUBSTITUTES
TABLE 007. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY TYPE
TABLE 008. OCALIVA MARKET OVERVIEW (2016-2028)
TABLE 009. URSODIOL MARKET OVERVIEW (2016-2028)
TABLE 010. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 011. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY APPLICATION
TABLE 012. HOSPITAL MARKET OVERVIEW (2016-2028)
TABLE 013. PRIVATE CLINIC MARKET OVERVIEW (2016-2028)
TABLE 014. OTHER MARKET OVERVIEW (2016-2028)
TABLE 015. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 016. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 017. N PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 018. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 019. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 020. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 021. ASIA PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 022. ASIA PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 023. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 025. MIDDLE EAST & AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 026. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 027. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 028. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 029. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 030. ALLERGAN PLC: SNAPSHOT
TABLE 031. ALLERGAN PLC: BUSINESS PERFORMANCE
TABLE 032. ALLERGAN PLC: PRODUCT PORTFOLIO
TABLE 033. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 033. ABBOTT LABORATORIES: SNAPSHOT
TABLE 034. ABBOTT LABORATORIES: BUSINESS PERFORMANCE
TABLE 035. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 036. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 036. TAKEDA PHARMACEUTICAL CO. LTD.: SNAPSHOT
TABLE 037. TAKEDA PHARMACEUTICAL CO. LTD.: BUSINESS PERFORMANCE
TABLE 038. TAKEDA PHARMACEUTICAL CO. LTD.: PRODUCT PORTFOLIO
TABLE 039. TAKEDA PHARMACEUTICAL CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. ELI LILLY AND CO.: SNAPSHOT
TABLE 040. ELI LILLY AND CO.: BUSINESS PERFORMANCE
TABLE 041. ELI LILLY AND CO.: PRODUCT PORTFOLIO
TABLE 042. ELI LILLY AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. INTERCEPT PHARMACEUTICALS INC.: SNAPSHOT
TABLE 043. INTERCEPT PHARMACEUTICALS INC.: BUSINESS PERFORMANCE
TABLE 044. INTERCEPT PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 045. INTERCEPT PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET COMPETITIVE RIVALRY
TABLE 005. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET THREAT OF NEW ENTRANTS
TABLE 006. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET THREAT OF SUBSTITUTES
TABLE 007. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY TYPE
TABLE 008. OCALIVA MARKET OVERVIEW (2016-2028)
TABLE 009. URSODIOL MARKET OVERVIEW (2016-2028)
TABLE 010. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 011. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET BY APPLICATION
TABLE 012. HOSPITAL MARKET OVERVIEW (2016-2028)
TABLE 013. PRIVATE CLINIC MARKET OVERVIEW (2016-2028)
TABLE 014. OTHER MARKET OVERVIEW (2016-2028)
TABLE 015. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 016. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 017. N PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 018. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 019. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 020. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 021. ASIA PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 022. ASIA PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 023. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 025. MIDDLE EAST & AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 026. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 027. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY TYPE (2016-2028)
TABLE 028. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY APPLICATION (2016-2028)
TABLE 029. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY COUNTRY (2016-2028)
TABLE 030. ALLERGAN PLC: SNAPSHOT
TABLE 031. ALLERGAN PLC: BUSINESS PERFORMANCE
TABLE 032. ALLERGAN PLC: PRODUCT PORTFOLIO
TABLE 033. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 033. ABBOTT LABORATORIES: SNAPSHOT
TABLE 034. ABBOTT LABORATORIES: BUSINESS PERFORMANCE
TABLE 035. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 036. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 036. TAKEDA PHARMACEUTICAL CO. LTD.: SNAPSHOT
TABLE 037. TAKEDA PHARMACEUTICAL CO. LTD.: BUSINESS PERFORMANCE
TABLE 038. TAKEDA PHARMACEUTICAL CO. LTD.: PRODUCT PORTFOLIO
TABLE 039. TAKEDA PHARMACEUTICAL CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. ELI LILLY AND CO.: SNAPSHOT
TABLE 040. ELI LILLY AND CO.: BUSINESS PERFORMANCE
TABLE 041. ELI LILLY AND CO.: PRODUCT PORTFOLIO
TABLE 042. ELI LILLY AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. INTERCEPT PHARMACEUTICALS INC.: SNAPSHOT
TABLE 043. INTERCEPT PHARMACEUTICALS INC.: BUSINESS PERFORMANCE
TABLE 044. INTERCEPT PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 045. INTERCEPT PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY TYPE
FIGURE 012. OCALIVA MARKET OVERVIEW (2016-2028)
FIGURE 013. URSODIOL MARKET OVERVIEW (2016-2028)
FIGURE 014. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 015. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY APPLICATION
FIGURE 016. HOSPITAL MARKET OVERVIEW (2016-2028)
FIGURE 017. PRIVATE CLINIC MARKET OVERVIEW (2016-2028)
FIGURE 018. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 019. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. ASIA PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. MIDDLE EAST & AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY TYPE
FIGURE 012. OCALIVA MARKET OVERVIEW (2016-2028)
FIGURE 013. URSODIOL MARKET OVERVIEW (2016-2028)
FIGURE 014. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 015. PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY APPLICATION
FIGURE 016. HOSPITAL MARKET OVERVIEW (2016-2028)
FIGURE 017. PRIVATE CLINIC MARKET OVERVIEW (2016-2028)
FIGURE 018. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 019. NORTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. EUROPE PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. ASIA PACIFIC PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. MIDDLE EAST & AFRICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. SOUTH AMERICA PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
